Late Friday, BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the FDA, in response to a request from the U.S. Centers ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE